-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Downgrades Terns Pharma to Hold, Lowers Price Target to $53

Benzinga·03/31/2026 14:57:36
Listen to the news
Truist Securities analyst Srikripa Devarakonda downgrades Terns Pharma (NASDAQ:TERN) from Buy to Hold and lowers the price target from $56 to $53.